Database

Startups

Main Industry
Biotechnology
Main Product/Service
1. Protein Drugs
2. Small Molecule Pharmaceuticals
3. Generic Drugs
Founded Year
2014
Unified Business No.
24626617
Status
Active
Number of Employees
0
Total Paid-in Capital
1,181,902,050 (NT$)
Location of Company
Taiwan , Hsinchu County
Exit Status
Emerging Stock Exchange(2021)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you. Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
About the Company
UBI Pharma Inc., established on July 31, 2014, is a trailblazing force in the pharmaceutical industry. We take pride in being the first pharmaceutical company in Asia (excluding Japan) to successfully pass the rigorous US FDA inspection for our injection filling production line. With over two decades of experience in the pharmaceutical sector, we have forged a path dedicated to pioneering long-acting protein drugs and specialized injectables. Our dedicated team, comprised of nearly 300 professionals, with almost 30% holding master's degrees or higher, operates from our headquarters and state-of-the-art manufacturing center situated in Hsinchu Industrial Park, covering an impressive 240,000 square feet. Additionally, we have strategically established clinical centers and business hubs in Taipei.



More ↓

Similar Companies

EIRGENIX, INC.

1. Trastuzumab Biosimilar
2. CDMO Services
3. CRM197 Carrier Protein
4. COVID-19 Antigen Rapid Test

ANYA BIOPHARM INC.

ORAL PEPTIDE
Summary of development timelines-product
MIRA/JE® Design
Lead Optimization
Preclinical Studies
Phase I
Phase II
Phase III
ANY002 Oral GLP1 product A: Prototype with human PK results available
ANY004 Oral GLP1 product B: Prototype in animal st